Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells 2,800 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 2,800 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total transaction of $147,840.00. Following the completion of the sale, the general counsel directly owned 87,815 shares in the company, valued at $4,636,632. This trade represents a 3.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock traded down $1.06 during midday trading on Thursday, reaching $48.87. The stock had a trading volume of 3,284,940 shares, compared to its average volume of 1,997,127. The stock’s 50-day simple moving average is $54.27 and its 200 day simple moving average is $57.34. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The stock has a market capitalization of $4.69 billion, a PE ratio of -7.50 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. During the same period in the prior year, the company posted ($1.01) EPS. The company’s revenue for the quarter was down 97.8% on a year-over-year basis. Equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Trending Headlines about CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY2025 commercial progress — CRSP reported growth in commercial revenue driven by CASGEVY (reported $116M for FY25, $54M in Q4), which supports the long‑term commercial thesis for the company’s lead product. CRSP FY25 revenue
• Positive Sentiment: Institutional interest — reports show notable additions by some funds (including ARK Invest) in recent quarters, a sign that selective investors see upside at current levels. This can provide a backstop for shares over time. ARK buys
• Neutral Sentiment: Analyst model tweaks — Brookline Capital made small downward tweaks to FY2028–FY2030 EPS forecasts (minor reductions in multi‑year projections). These adjustments are modest and reflect model updates rather than new negative clinical data. (Source: Brookline reports)
• Neutral Sentiment: Short‑interest data appears anomalous — filings in mid‑March show zero reported short interest in the dataset provided, a likely reporting artifact; days‑to‑cover is effectively 0.0 in those numbers, so this item offers no clear directional signal. (Data summary)
• Negative Sentiment: Upsized $550M convertible senior notes offering — CRSP priced $550M of convertible notes due 2031 (upsized from $350M) with an initial conversion price ~ $76.56 (≈45% premium to pre‑deal price). While proceeds (~$536M net) bolster liquidity, the deal introduces potential future dilution if conversions occur and the upsizing/offer timing likely pressured the share price today. Convertible notes PR
• Negative Sentiment: Near‑term market reaction — news flow around the financing and profit taking led to a sharp intraday decline in recent sessions, reinforcing that the convertible deal + analyst updates are the primary drivers of today’s weakness. Market dip

Analyst Upgrades and Downgrades

A number of analysts have commented on CRSP shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Evercore reissued an “outperform” rating and issued a $74.00 target price on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Citigroup reiterated a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, February 16th. Needham & Company LLC lifted their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Finally, Chardan Capital raised their price objective on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a research note on Saturday, February 14th. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $64.24.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. GSK plc bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $168,890,000. Orbis Allan Gray Ltd grew its holdings in CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock valued at $134,467,000 after purchasing an additional 1,201,600 shares during the period. Geode Capital Management LLC increased its stake in shares of CRISPR Therapeutics by 98.1% in the second quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company’s stock worth $100,789,000 after purchasing an additional 1,025,979 shares in the last quarter. SR One Capital Management LP raised its stake in CRISPR Therapeutics by 94.4% during the 3rd quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock valued at $132,132,000 after purchasing an additional 989,812 shares during the period. Finally, State Street Corp lifted its stake in CRISPR Therapeutics by 35.6% in the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after purchasing an additional 859,334 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.